RxDoctor Payments DataLook up a doctor →

Jeannette Hart, PA

Physician Assistant · Richland, WANPI 1962753830

Payments from drug & device makers

$262,680in general payments, 2019–2025

Across 643 payments — averaging $408.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$134K
  • AstraZeneca$67K
  • Johnson & Johnson$35K
  • Sanofi$11K
  • Boehringer Ingelheim$8K
  • GSK$4K
  • plus $5K from 21 others

What the payments were for

  • Consulting fees$30,24112%
  • Speaking & faculty fees$138,99753%
  • Travel & lodging$78,98030%
  • Food & beverage$14,3065%
  • Education$1560%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$262,680 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$88,699
Medicare patients
403
Services billed
1,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab44$310,479
RinvoqUpadacitinib33$205,254
Enbrel SureclickEtanercept26$193,664
Cimzia (2 Pack)Certolizumab Pegol18$151,410
Xeljanz XrTofacitinib Citrate15$112,967
Orencia ClickjectAbatacept16$90,111
OtezlaApremilast14$80,014
Humira(Cf)Adalimumab11$76,538
Actemra ActpenTocilizumab15$68,133
Hydroxychloroquine Sulfate461$21,050
MethotrexateMethotrexate Sodium535$15,388
Leflunomide123$7,928
Febuxostat27$5,458
Sulfasalazine146$5,214
Celecoxib59$3,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$133,669$281,79244 claims
UCB, Inc.Cimzia (2 Pack)$224$151,41018 claims
AmgenOtezla$800$80,01414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Richland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →